No Data
No Data
ITeos Therapeutics Down Over 29%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
ITeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Market-Moving News for September 16th
ITeos Therapeutics Analyst Ratings
Piper Sandler Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $36
ITeos Therapeutics Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab
Gobinath OP :